|
Sign In to gain access to subscriptions and/or personal tools.
|
Is Antibiotic Prophylaxis for Bacterial Endocarditis Cost-Effective?
Zia Agha, MD, MS
Division of General Internal Medicine, Medical College of Wisconsin, Zablocki Veterans Affairs Medical Center, Milwaukee, Wisconsin, zia{at}mcw.edu
Richard P. Lofgren, MD, MPH
Division of General Internal Medicine, Medical College of Wisconsin
Jerome V. VanRuiswyk, MD, MS
Division of General Internal Medicine, Medical College of Wisconsin, Zablocki Veterans Affairs Medical Center, Milwaukee, Wisconsin
Background. Antibiotic prophylaxis for bacterial endocarditis is recommended by the American Heart Association (AHA) before undergoing certain dental procedures. Whether such antibiotic prophylaxis is cost-effective is not clear. The authors’ objective is to estimate the cost-effectiveness of predental antibiotic prophylaxis in patients with underlying heart disease. Methods. The authors conducted a cost-effectiveness analysis using a Markov model to compare cost-effectiveness of 7 antibiotic regimens per AHA guidelines and a no prophylaxis strategy. The study population consisted of a hypothetical cohort of 10 million patients with either a high or moderate risk for developing endocarditis. Results. Prophylaxis for patients with moderate or high risk for endocarditis cost $88,007/quality-adjusted life years saved if clarithromycin was used. Prophylaxis with amoxicillin and ampicillin resulted in a net loss of lives. All other regimens were less cost-effective than clarithromycin. For 10 million persons, clarithromycin prophylaxis prevented 119 endocarditis cases and saved 19 lives. Conclusion. Predental antibiotic prophylaxis is cost-effective only for persons with moderate or high risk of developing endocarditis. Contrary to current recommendations, our data demonstrate that amoxicillin and ampicillin are not cost-effective and should not be considered the agents of choice. Clarithromycin should be considered the drug of choice and cephalexin as an alternative drug of choice. The current published guidelines and recommendations should be revised.
Key Words: bacterial endocarditis • chemoprevention • antibiotic prophylaxis • cost and cost analysis
Medical Decision Making, Vol. 25, No. 3,
308-320 (2005)
DOI: 10.1177/0272989X05276852
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
P. P. Gopalakrishnan, S. K. Shukla, and T. Tak
Infective Endocarditis: Rationale for Revised Guidelines for Antibiotic Prophylaxis
Clin. Med. Res.,
September 1, 2009;
7(3):
63 - 68.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Brooks
Prophylactic antibiotic treatment to prevent infective endocarditis: new guidance from the National Institute for Health and Clinical Excellence
Heart,
May 1, 2009;
95(9):
774 - 780.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B D Prendergast, J L Harrison, and C K Naber
Commentary on endocarditis prophylaxis: a quaint custom or medical necessity?
Heart,
July 1, 2008;
94(7):
931 - 934.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Wilson, K. A. Taubert, M. Gewitz, P. B. Lockhart, L. M. Baddour, M. Levison, A. Bolger, C. H. Cabell, M. Takahashi, R. S. Baltimore, et al.
Prevention of infective endocarditis: Guidelines from the American Heart Association: A guideline from the American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group
J Am Dent Assoc,
January 1, 2008;
139(suppl_1):
3S - 24S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Wilson, K. A. Taubert, M. Gewitz, P. B. Lockhart, L. M. Baddour, M. Levison, A. Bolger, C. H. Cabell, M. Takahashi, R. S. Baltimore, et al.
Prevention of Infective Endocarditis: Guidelines From the American Heart Association: A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group
Circulation,
October 9, 2007;
116(15):
1736 - 1754.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Wilson, K. A. Taubert, M. Gewitz, P. B. Lockhart, L. M. Baddour, M. Levison, A. Bolger, C. H. Cabell, M. Takahashi, R. S. Baltimore, et al.
Prevention of infective endocarditis: Guidelines from the American Heart Association: A guideline from the American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group
J Am Dent Assoc,
June 1, 2007;
138(6):
739 - 760.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. G Bogle and H. Ashrafian
The authors reply
Heart,
June 1, 2007;
93(6):
753 - 754.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. B. Seto
The Case for Infectious Endocarditis Prophylaxis: Time to Move Forward
Arch Intern Med,
February 26, 2007;
167(4):
327 - 330.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Morris
Coming Clean With Antibiotic Prophylaxis for Infective Endocarditis
Arch Intern Med,
February 26, 2007;
167(4):
330 - 332.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. K. Gould, T. S. J. Elliott, J. Foweraker, M. Fulford, J. D. Perry, G. J. Roberts, J. A. T. Sandoe, and R. W. Watkin
Guidelines for the prevention of endocarditis: report of the Working Party of the British Society for Antimicrobial Chemotherapy--authors' response
J. Antimicrob. Chemother.,
October 1, 2006;
58(4):
896 - 898.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Singh, C. D. Joyner, and D. A. Alter
The importance of echocardiography in physicians' support of endocarditis prophylaxis.
Arch Intern Med,
March 13, 2006;
166(5):
549 - 553.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
